JP2019516765A5 - - Google Patents

Download PDF

Info

Publication number
JP2019516765A5
JP2019516765A5 JP2018561686A JP2018561686A JP2019516765A5 JP 2019516765 A5 JP2019516765 A5 JP 2019516765A5 JP 2018561686 A JP2018561686 A JP 2018561686A JP 2018561686 A JP2018561686 A JP 2018561686A JP 2019516765 A5 JP2019516765 A5 JP 2019516765A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
compound
formula
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018561686A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019516765A (ja
JP7141108B2 (ja
Filing date
Publication date
Priority claimed from GBGB1609222.3A external-priority patent/GB201609222D0/en
Application filed filed Critical
Publication of JP2019516765A publication Critical patent/JP2019516765A/ja
Publication of JP2019516765A5 publication Critical patent/JP2019516765A5/ja
Application granted granted Critical
Publication of JP7141108B2 publication Critical patent/JP7141108B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018561686A 2016-05-25 2017-05-25 医薬製剤 Active JP7141108B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1609222.3 2016-05-25
GBGB1609222.3A GB201609222D0 (en) 2016-05-25 2016-05-25 Pharmaceutical formulation
PCT/GB2017/051494 WO2017203270A1 (en) 2016-05-25 2017-05-25 Pharmaceutical formulation

Publications (3)

Publication Number Publication Date
JP2019516765A JP2019516765A (ja) 2019-06-20
JP2019516765A5 true JP2019516765A5 (https=) 2020-07-02
JP7141108B2 JP7141108B2 (ja) 2022-09-22

Family

ID=56369959

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018561686A Active JP7141108B2 (ja) 2016-05-25 2017-05-25 医薬製剤

Country Status (25)

Country Link
US (2) US10973821B2 (https=)
EP (1) EP3463365B1 (https=)
JP (1) JP7141108B2 (https=)
KR (1) KR102464150B1 (https=)
CN (1) CN109982704B (https=)
AU (1) AU2017270942B2 (https=)
CA (1) CA3024771A1 (https=)
CY (1) CY1124733T1 (https=)
DK (1) DK3463365T3 (https=)
ES (1) ES2888951T3 (https=)
GB (1) GB201609222D0 (https=)
HR (1) HRP20211795T1 (https=)
HU (1) HUE056129T2 (https=)
IL (1) IL263167B (https=)
LT (1) LT3463365T (https=)
MA (1) MA45126A (https=)
MX (1) MX382199B (https=)
MY (1) MY197663A (https=)
PL (1) PL3463365T3 (https=)
PT (1) PT3463365T (https=)
RU (1) RU2760681C2 (https=)
SG (1) SG11201810323RA (https=)
SI (1) SI3463365T1 (https=)
WO (1) WO2017203270A1 (https=)
ZA (1) ZA201807851B (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201609222D0 (en) * 2016-05-25 2016-07-06 F2G Ltd Pharmaceutical formulation
US11819503B2 (en) 2019-04-23 2023-11-21 F2G Ltd Method of treating coccidioides infection
JP2023523295A (ja) * 2020-04-26 2023-06-02 アポロミクス インコーポレイテッド C-met阻害剤のための新規医薬製剤
CN113429396A (zh) * 2021-06-08 2021-09-24 深圳市祥根生物医药有限公司 一种五元杂芳环衍生物及其制备方法和用途

Family Cites Families (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1051723A (https=) 1962-04-27
US3202654A (en) 1962-04-27 1965-08-24 Bristol Myers Co 6-[alpha-hydroxy-and alpha-amino-alpha-pyrrolylacetamido] penicillanic acids and salts thereof
US3252970A (en) 1963-02-27 1966-05-24 Ciba Geigy Corp Aromatization
BE631632A (https=) 1963-04-26
US3268558A (en) 1964-11-05 1966-08-23 Ortho Pharma Corp 1-r-2, 4-dinitropyrroles
US3458515A (en) 1966-07-21 1969-07-29 American Home Prod Piperazine substituted pyrroles
GB1208014A (en) 1967-03-23 1970-10-07 Glaxo Lab Ltd Cephalosporins
US3573294A (en) 1968-03-14 1971-03-30 Glaxo Lab Ltd 7 - (arylglyoxamido)cephalosporanic acids and their salts and alpha-carbonyl derivatives
BE790747A (fr) 1971-10-30 1973-02-15 Whitefin Holding Sa Stereo-isomeres du 1-(1'-(0-chloro-benzyl)-pyrrol-2'-yl) -2-dibutyl sec.-amino-ethanol et procede pour leur preparation
GB1476503A (en) 1973-06-21 1977-06-16 Sterling Drug Inc 1-arylamino-and 1-arylimino-pyrroles and preparation thereof
BE848465A (fr) 1976-11-18 1977-03-16 Stereo-isomeres de 1-(1'-benzyl-2' pyrryl)-2-disec.butylaminoethanols a activite analgesique et preparations pharmaceutiques qui les contiennent
US4316900A (en) 1977-10-05 1982-02-23 Ciba-Geigy Corporation Piperazinopyrrolobenzodiazepines
JPS57142966A (en) 1981-02-27 1982-09-03 Sagami Chem Res Center (1-alkyl-2-pyrrolyl)glyoxylic acid amide derivative
JPS57144255A (en) 1981-03-03 1982-09-06 Sagami Chem Res Center Alpha-methylthio(1-alkyl-2-pyrrolyl)acetamide derivative
US4761424A (en) 1985-10-01 1988-08-02 Warner-Lambert Company Enolamides, pharmaceutical compositions and methods for treating inflammation
FR2601368B1 (fr) 1986-07-08 1989-04-07 Synthelabo Derives de nitrofuranne, leur preparation et leur application en therapeutique.
AU650953B2 (en) 1991-03-21 1994-07-07 Novartis Ag Inhaler
US5637592A (en) 1994-07-12 1997-06-10 Janssen Pharmaceutica N.V. Acyl derivatives of azolones
BR9508298A (pt) 1994-07-21 1998-11-03 Shionogi & Co Inibidores de indolizina de spla2
EP0823423B1 (en) 1995-04-28 2004-06-16 Banyu Pharmaceutical Co., Ltd. 1,4-disubstituted piperidine derivatives
EP0747756B1 (en) 1995-06-06 2000-05-24 Agfa-Gevaert N.V. Photographic materials
JPH09249669A (ja) 1996-03-13 1997-09-22 Ono Pharmaceut Co Ltd 縮合ピロール誘導体、およびそれらを有効成分として含有する薬剤
WO1998056422A1 (en) 1997-06-13 1998-12-17 The University Of Kansas Polar drug or prodrug compositions with extended shelf-life storage and a method of making thereof
ATE364374T1 (de) 1997-08-11 2007-07-15 Pfizer Prod Inc Feste pharmazeutische dispersionen mit erhöhter bioverfügbarkeit
US6331537B1 (en) 1998-06-03 2001-12-18 Gpi Nil Holdings, Inc. Carboxylic acids and carboxylic acid isosteres of N-heterocyclic compounds
WO1999062881A1 (en) 1998-06-03 1999-12-09 Gpi Nil Holdings, Inc. Aza-heterocyclic compounds used to treat neurological disorders and hair loss
ES2310164T3 (es) 1999-02-10 2009-01-01 Pfizer Products Inc. Dispositivo de liberacion controlada por la matriz.
AU768491B2 (en) 1999-05-04 2003-12-11 Janssen Pharmaceutica N.V. Antifungal ethers
WO2001008572A1 (de) 1999-07-30 2001-02-08 Norbert Heske Kanülenanordnung zum einbringen endoskopischer instrumente in einen menschlichen oder tierischen körper
GEP20053427B (en) 1999-12-23 2005-01-25 Pfizer Prod Inc Pharmaceutical Compositions Providing Enhanced Drug Concentrations
GB0011089D0 (en) 2000-05-08 2000-06-28 Black James Foundation Gastrin and cholecystokinin receptor ligands (11)
US7202239B2 (en) 2001-04-12 2007-04-10 Wyeth Cyclohexylphenyl carboxamides tocolytic oxytocin receptor antagonists
US6825201B2 (en) 2001-04-25 2004-11-30 Bristol-Myers Squibb Company Indole, azaindole and related heterocyclic amidopiperazine derivatives
EP1399442B1 (en) 2001-06-06 2006-08-09 Vertex Pharmaceuticals Incorporated Cak inhibitors and uses thereof
JP4128138B2 (ja) 2001-06-20 2008-07-30 第一三共株式会社 ジアミン誘導体
TW200306819A (en) 2002-01-25 2003-12-01 Vertex Pharma Indazole compounds useful as protein kinase inhibitors
PL371593A1 (en) 2002-02-01 2005-06-27 Pfizer Products Inc. Method for making homogeneous spray-dried solid amorphous drug dispersions using pressure nozzles
EP1469833B1 (en) 2002-02-01 2021-05-19 Bend Research, Inc. Method for making homogeneous spray-dried solid amorphous drug dispersions utilizing modified spray-drying apparatus
US20040162298A1 (en) 2002-02-23 2004-08-19 Hsu-Tso Ho Method of treating HIV infection by preventing interaction of CD4 and gp120
EP1543841A4 (en) 2002-08-15 2011-03-16 Yunqing Liu SOLID PHARMACEUTICAL NANO FORMULATION AND MANUFACTURING METHOD THEREFOR
US20050032871A1 (en) 2002-09-03 2005-02-10 Sugen, Inc. Sulfonylated pyrrole-2-indolinone derivatives as kinase inhibitors
CA2517034A1 (en) 2003-03-13 2004-09-30 Synta Pharmaceuticals Corp. Fused pyrrole compounds
FR2854079B1 (fr) 2003-04-25 2007-11-30 Pf Medicament Procede de preparation de complexes moleculaires
CL2004001884A1 (es) 2003-08-04 2005-06-03 Pfizer Prod Inc Procedimiento de secado por pulverizacion para la formacion de dispersiones solidas amorfas de un farmaco y polimeros.
JP2007509173A (ja) 2003-10-24 2007-04-12 シエーリング アクチエンゲゼルシャフト インドリノン誘導体類及び疾病状態、例えば癌の処理へのそれらの使用
WO2005115330A2 (en) 2004-05-28 2005-12-08 Pfizer Products Inc. Pharmaceutical compositions with enhanced performance
US20060058286A1 (en) 2004-09-16 2006-03-16 Mark Krystal Methods of treating HIV infection
EP1844078B1 (en) 2005-02-03 2016-09-28 Bend Research, Inc Pharmaceutical compositions with enhanced performance
NZ562034A (en) 2005-03-31 2009-10-30 Janssen Pharmaceutica Nv Bicyclic pyrazole compounds as antibacterial agents
AR053713A1 (es) 2005-04-20 2007-05-16 Xenon Pharmaceuticals Inc Compuestos heterociclicos y sus usos como agentes terapeuticos
ATE420639T1 (de) 2005-05-18 2009-01-15 F2G Ltd Antimykotische mittel
US20090176837A1 (en) 2005-07-12 2009-07-09 Sony Corporation Compounds with activity at retinoic acid receptors
WO2007015866A2 (en) 2005-07-20 2007-02-08 Kalypsys, Inc. Inhibitors of p38 kinase and methods of treating inflammatory disorders
TWI428125B (zh) 2006-03-20 2014-03-01 Vertex Pharma 對包括vx-950之藥物實施噴霧乾燥之方法及由此方法製備之產物
US8343548B2 (en) 2006-08-08 2013-01-01 Shin-Etsu Chemical Co., Ltd. Solid dosage form comprising solid dispersion
US20080118500A1 (en) 2006-11-16 2008-05-22 Taiwan Liposome Company Sustained releasing composition via local injection for treating eye diseases
GB0623209D0 (en) 2006-11-21 2007-01-03 F2G Ltd Antifungal agents
JP5508859B2 (ja) 2007-01-26 2014-06-04 アイエスピー インヴェストメンツ インコーポレイテッド 噴霧乾燥製品を製造するための調剤処理方法
CN101260086B (zh) 2007-03-06 2011-08-10 中国科学院上海药物研究所 蛋白酪氨酸磷酸酯酶1b抑制剂及其制备方法和用途
GB0710121D0 (en) 2007-05-25 2007-07-04 F2G Ltd Antifungal agents
US20100215747A1 (en) 2007-07-13 2010-08-26 Corey Jay Bloom Nanoparticles comprising ionizable, poorly water soluble cellulosic polymers
DK2626361T3 (en) 2008-04-24 2015-01-19 F2G Ltd Pyrrol-Antimycotics
GB0809773D0 (en) 2008-05-29 2008-07-09 F2G Ltd Antifungal combination therapy
US20100093872A1 (en) 2008-10-15 2010-04-15 Erimos Pharmaceuticals Llc Stable aqueous formulations of water insoluble or poorly soluble drugs
CA2760305A1 (en) 2009-04-28 2010-11-04 Boehringer Ingelheim International Gmbh Ex-vivo treatment of immunological disorders with pkc-theta inhibitors
JP5792807B2 (ja) 2010-06-14 2015-10-14 ダウ グローバル テクノロジーズ エルエルシー アセテートおよびサクシネートの置換が向上されたヒドロキシプロピルメチルセルロースアセテートサクシネート
US9084976B2 (en) 2010-09-03 2015-07-21 Bend Research, Inc. Spray-drying apparatus and methods of using the same
WO2012060448A1 (ja) 2010-11-05 2012-05-10 エーザイ・アール・アンド・ディー・マネジメント株式会社 抗真菌剤としての併用医薬組成物
CN102805733B (zh) 2011-06-01 2016-03-09 日东电工株式会社 颗粒制剂及其制造方法
ES2784629T3 (es) 2011-11-29 2020-09-29 Jurox Pty Ltd Composiciones farmacéuticas inyectables estables que comprenden 2-hidroxipropil-beta-ciclodextrina y alfaxalona
EP2836205B1 (en) 2012-04-11 2016-10-19 Dow Global Technologies LLC Esterified cellulose ethers having a specific substituent distribution
MX2015002430A (es) 2012-08-24 2015-06-22 Dow Global Technologies Llc Acetato-succinatos de hidroxialquilmetilcelulosa.
EP2888289B1 (en) 2012-08-24 2019-08-07 Dow Global Technologies LLC Partially cross-linked esterified cellulose ethers
CN112353762A (zh) 2013-01-22 2021-02-12 霍夫曼-拉罗奇有限公司 具有改善的生物利用度的药物组合物
EP3021832B9 (en) 2013-07-19 2023-03-15 Boehringer Ingelheim Vetmedica GmbH Preserved etherified cyclodextrin derivatives containing liquid aqueous pharmaceutical composition
WO2015007759A1 (en) 2013-07-19 2015-01-22 Boehringer Ingelheim Vetmedica Gmbh Etherified cyclodextrin derivatives containing liquid aqueous pharmaceutical composition
EP3076951B1 (en) 2013-12-05 2020-09-30 Celal Albayrak Process for the production of drug formulations for oral administration
PT107568B (pt) 2014-03-31 2018-11-05 Hovione Farm S A Processo de secagem por atomização para a produção de pós com propriedades melhoradas.
CA2982660C (en) * 2014-11-21 2023-01-24 F2G Limited 2-(1,5-dimethyl-3-phenyl-1h-pyrrol-2-yl)-n-(4-(4-(5-fluoropyrimidin-2-yl)piperazine-1-yl)phenyl)-2-oxoacetamide and derivatives thereof for use as antifungal agents
GB201609222D0 (en) * 2016-05-25 2016-07-06 F2G Ltd Pharmaceutical formulation

Similar Documents

Publication Publication Date Title
ES2390661T5 (es) Forma de presentación para administración por vía oral para éster etílico de ácido 3-[(2-{[4-(hexiloxicarbonilamino-imino-metil)-fenilamino]-metil}-1-metil-1H-bencimidazol-5-carbonil)-piridin-2-il-amino]-propiónico o sus sales
TWI540128B (zh) 醫藥組合物
CN1886120B (zh) 用于制备可口腔给药的固态药物组合物的方法
ES2988678T3 (es) Un comprimido que comprende un derivado de metoxiurea y partículas de manitol
CN106255496B (zh) 包括紫杉烷的无定形固体分散体、包括其的片剂以及用于制备其的方法
RU2489149C2 (ru) Стабилизированные аморфные формы иматиниба мезилата
JP2019524883A5 (https=)
JP2014523445A5 (https=)
JP2009530415A5 (https=)
WO2017140254A1 (zh) 一种含有jak激酶抑制剂或其可药用盐的药物组合物
JP2019516765A5 (https=)
JP2008533007A5 (https=)
JP2014525449A5 (https=)
JP2024544572A (ja) Rock2阻害剤のナノ結晶製剤およびその調製方法
RU2018142381A (ru) Фармацевтический препарат
CN105358149A (zh) 粉防己碱家族的药物制剂和方法
CN101827584A (zh) N-芳基脲基药物的固态分散体产品
JP2018502118A (ja) 非晶質ヘミフマル酸テノホビルアラフェナミドおよびその予備混合物を調製するプロセス
KR101282847B1 (ko) 실로스타졸을 함유하는 고체분산체 및 이를 포함하는 약학 조성물
CN101190912A (zh) 新的抗病毒化合物及其制备方法
KR102276281B1 (ko) 의약으로 사용하기 위한 펄린돌 광학이성질체의 약학적으로 허용가능한 염
CN107072954B (zh) 用于口服给药的包含洛贝格列酮的药物组合物
TWI558400B (zh) 苯基尿嘧啶化合物之調配物
JP2015189677A (ja) ソリフェナシン非晶質体を含有する医薬組成物
JP2016538312A (ja) 非晶質のコビシスタットの固体分散体